Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing T cell engaging (TCE) bispecific antibodies for solid tumors. Its pipeline includes CTIM-76 (CLDN6 x CD3 TCE) in Phase 1 for gynecologic and testicular cancers, CT-95 (MSLN x CD3 TCE) in Phase 1, and CT-202 (Nectin-4 x CD3 TCE) preparing for first-in-human trials. The company retains full worldwide development and commercialization rights to its key product candidates.
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001628280-26-020498 | EDGAR | 61K words |
| 2025-03-20 | 2024-12-31 | 0001842952-25-000028 | EDGAR | 57K words |
| 2024-03-21 | 2023-12-31 | 0001842952-24-000011 | EDGAR | 53K words |
| 2023-03-22 | 2022-12-31 | 0001842952-23-000041 | EDGAR | — |
| 2022-03-23 | 2021-12-31 | 0001842952-22-000029 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001628280-26-053347 | EDGAR | 20K words |
| 2025-11-05 | 2025-09-30 | 0001628280-25-049533 | EDGAR | 19K words |
| 2025-08-06 | 2025-06-30 | 0001842952-25-000081 | EDGAR | 16K words |
| 2025-05-07 | 2025-03-31 | 0001842952-25-000048 | EDGAR | 16K words |
| 2024-11-06 | 2024-09-30 | 0001842952-24-000085 | EDGAR | 16K words |
| 2024-08-07 | 2024-06-30 | 0001842952-24-000065 | EDGAR | 15K words |
| 2024-05-08 | 2024-03-31 | 0001842952-24-000035 | EDGAR | 14K words |
| 2023-11-09 | 2023-09-30 | 0001842952-23-000085 | EDGAR | 15K words |
| 2023-08-09 | 2023-06-30 | 0001842952-23-000078 | EDGAR | 15K words |
| 2023-05-10 | 2023-03-31 | 0001842952-23-000054 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001842952-22-000096 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001842952-22-000071 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0001628280-26-053378 | EDGAR | 5K words |
| 2026-07-31 | 0001628280-26-051399 | EDGAR | 1K words |
| 2026-04-02 | 0001628280-26-022931 | EDGAR | 1K words |
| 2026-03-23 | 0001628280-26-020517 | EDGAR | 4K words |
| 2026-03-13 | 0001628280-26-017691 | EDGAR | 1K words |
| 2026-02-27 | 0001628280-26-012813 | EDGAR | 1K words |
| 2026-01-08 | 0001628280-26-001275 | EDGAR | 5K words |
| 2025-11-05 | 0001628280-25-049604 | EDGAR | 1K words |
| 2025-10-24 | 0001628280-25-046258 | EDGAR | 1K words |
| 2025-10-20 | 0001628280-25-045513 | EDGAR | 1K words |
87 total filings indexed. 60 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001842952 |
| Ticker | CNTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.contexttherapeutics.com |
| Listed | 2021-10-20 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CNTX (~200 tokens, structured JSON with cryptographic provenance)